The Department of Veterans Affairs (VA) National Acquisition Center awarded a single-award Indefinite Delivery Contract (IDC) to Teva Pharmaceuticals USA, Inc., a foreign-owned pharmaceutical manufacturer, for the supply of glatiramer acetate injections. The $64,352,514.80 contract has a base period of one year and four one-year option periods, running from August 2023 to August 2025. This IDC will ensure the delivery of approximately 208,000 syringes of glatiramer acetate 20mg/mL and 40mg/mL annually to the VA, Department of Defense, Bureau of Prisons, and Indian Health Service. Teva Pharmaceuticals USA, Inc. has extensive experience supplying critical pharmaceutical products to various federal agencies, including the Adenovirus Type 4 vaccine, Albuterol HFA inhalers, and Levalbuterol HCL solution. The original solicitation, issued by the VA National Acquisition Center, was an unrestricted procurement with no set-aside designation. The contract will be distributed through the VA's and Department of Defense's Pharmaceutical Prime Vendor Programs.
Generated 1/7/25, 11:33 AM